Type: Product
Name: Zytiga
First reported 23 hours ago - Updated 23 hours ago - 1 reports

Bayer perceives there to be an increasingly more compelling outlook for Xofigo following strong Q3 2013

(live-PR.com) - Already positioned as one of the most commercially promising new drug approvals of 2013, Algeta and Bayer´s prostate cancer treatment Xofigo is now driving what appears to be the inevitable acquisition of the former by the latter. Buoyed ... [Published Live-PR.com - 23 hours ago]
Entities: Bayer AG, Algeta ASA, Zytiga
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Want to claim a name? FDA needs your input on locking down brand monikers

Start with an X or a Z. Make an active but abbreviated reference to a molecule. Advertising experts have a few tricks up their sleeves when concocting a drug's proprietary name--like Zytiga, Xtandi and Xeljanz--that might thrust the product to success. ... [Published FiercePharma - Jul 30 2014]
Entities: Xeljanz, Xtandi, Zytiga
First reported Jul 26 2014 - Updated Jul 26 2014 - 1 reports

3 Future Biotechnology Blockbusters?

The holy grail of drug development is launching a billion-dollar blockbuster therapy, but that isn't easy to do. It costs more than $1 billion to usher compounds through expensive clinical trials (including failures) and just 10% of drugs in pipelines ... [Published Motley Fool Discussion Boards - Jul 26 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

295% Pop: Too Late to Buy Puma Biotechnology Stock?

The news surprised investors, whose worries over side effects in previous trials caused shares to fall by more than 50%, as shares held short increased from 1.5 million to nearly 1.7 million, or roughly 8% of all Puma's shares available for trading.Delivering ... [Published Motley Fool - Jul 23 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

The prostate cancer therapeutics market will reach $7bn in 2014 according to new Visiongain report

vg - Jul. 18, 2014 - LONDON, U.K. -- These forecasts and others appear in visiongain’s latest report The Prostate Cancer Therapeutics Market Forecast 2014-2024: Opportunities for Leading Companies.The last few years have shown massive acceleration in ... [Published Prlog - Jul 18 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 2 reports

New drugs see J&J sales rise

Johnson & Johnson saw sales rise 9.1% to $19.5 billion year on year on the back of a strong performance from key brands including new hep C drug Olysio, blood thinner Xarelto and cancer treatment Zytiga.Worldwide pharma sales jumped 21.1% to $8.5 billion, ... [Published BioPortfolio - Jul 17 2014]
First reported Jul 15 2014 - Updated Jul 16 2014 - 5 reports

J&J logs $19.5B in Q2 sales

Share this article: Hepatitis C medication Olysio's $831 million in second-quarter sales beat analyst expectations, which hovered in the $617 million range, helping power Johnson & Johnson's quarterly revenue total of $19.5 billion, a 9% increase over ... [Published Medical Marketing And Media - Jul 15 2014]
First reported Jul 15 2014 - Updated Jul 16 2014 - 2 reports

New products drive 2nd-qtr growth for Johnson & Johnson

Global health care products giant Johnson & Johnson (NYSE: JNJ), the first pharma to report second-quarter 2014 financial results, said group revenue rose 9.1% to $19.5 billion and beating Wall Street forecasts of $18.85 billion.Notwithstanding, J&J’s ... [Published Pharma Letter - Jul 16 2014]
First reported Jul 15 2014 - Updated Jul 15 2014 - 2 reports

Olysio’s Stronger-Than-Expected Sales Drive Strong Quarter For J

Products launched since 2009 have yielded the highest pharmaceutical sales growth among the 10 biggest biopharma companies, more than offsetting a substantial patent cliff. Zytiga and Olysio already have passed the $1 billion sales threshold this year, ... [Published Health News Daily - Jul 15 2014]
Entities: Sales, Xarelto, Zytiga
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

BREAKING NEWS: J&J books 13% profit rise for second quarter

Johnson & Johnson has seen its profit jump 13% for the second quarter on the back of strong sales of its new generation medicines.The healthcare giant beat expectations with earnings of $4.3 billion for the period, compared to $3.8 billion posted a year ... [Published Pharma Times - Jul 15 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 2 reports

Earnings Preview: Abbott Laboratories and Johnson & Johnson

The health care sector in general, and biotech industry in particular, have now shrugged off their earlier first quarter dip. For instance, the iShares Nasdaq Biotech Index (NASDAQ: IBBWhat's key to understand is that this turnaround was ignited by a ... [Published Motley Fool - Jul 14 2014]
First reported Jul 07 2014 - Updated Jul 08 2014 - 2 reports

Is This Johnson & Johnson's Worst Nightmare?

Even so, there are two major threats to J&J's pharma business that could reverse this growth trend.Threat No. 1J&J's hepatitis C drug Olysio saw surprisingly strong sales in the first quarter, raking in a reported $354 million. The bulk of these sales ... [Published Motley Fool - Jul 08 2014]


...6 letters when used alongside Novartis " blockbuster drug Lucentis, versus 6.5 letters for Lucentis alone."
"A panel of 21 physicians from the European consensus panel of prostate cancer expert agreed and published in European Journal of Cancer that PROVENGE is an appropriate option for the treatment of asymptomatic, minimally symptomatic metastatic castrate resistant prostate cancer. 70% of these physicians support the use of PROVENGE prior to Abiraterone or Enzalutamide."
...new product launches and the progress we have made in achieving our near-term priorities," said Alex Gorsky , Chairman and Chief Executive Officer. "Significant advancements are being made in the treatment options and access to care for patients and customers around the world. Our diversified business model, focus on long-term growth drivers and talented colleagues position us well in this evolving and dynamic global healthhealth care market."
...Longson, Centre for Health Technology Evaluation Director at NICE, noted that as Xtandi works in a different way to other current options, and "as there are few treatments available for patients at this stage of prostate cancer, this is really good news for patients.”"

More Content

All (90) | News (78) | Reports (0) | Blogs (11) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Bayer perceives there to be an increasingly mor... [Published Live-PR.com - 23 hours ago]
Want to claim a name? FDA needs your input on l... [Published FiercePharma - Jul 30 2014]
Two Cancer Drugs from Astellas, BMS Win NICE Re... [Published FDA News - Jul 28 2014]
3 Future Biotechnology Blockbusters? [Published Motley Fool Discussion Boards - Jul 26 2014]
3 Convincing Reasons To Buy Dendreon [Published Seeking Alpha - Jul 24 2014]
Harvard Cubs at Adage Reap $1 Billion in a Day ... [Published Bloomberg - Jul 24 2014]
295% Pop: Too Late to Buy Puma Biotechnology St... [Published Motley Fool - Jul 23 2014]
Puma Biotech Soars on Positive Breast Cancer Dr... [Published Washington Post - Jul 23 2014]
Johnson & Johnson Reports 2014 Second-Quarter R... [Published HispanicBusiness.com - Jul 23 2014]
Cancer drugs Yervoy, Xtandi get NICE thumbs up [Published Pharma Times - Jul 23 2014]
Is this Exelixis Stock's Worst Nightmare? [Published Motley Fool - Jul 22 2014]
Dendreon Rating Reiterated by Zacks (DNDN) [Published American Banking News - Jul 18 2014]
The prostate cancer therapeutics market will re... [Published Prlog - Jul 18 2014]
New drugs see J&J sales rise [Published BioPortfolio - Jul 17 2014]
New drugs see J&J sales rise [Published Pharmafocus - Jul 17 2014]
BB BIOTECH AG: Biotech sector recovers from mar... [Published EuroInvestor - Jul 17 2014]
Olysio leads charge at J&J but competition is o... [Published PMLive - Jul 16 2014]
New products drive 2nd-qtr growth for Johnson &... [Published Pharma Letter - Jul 16 2014]
Olysio’s Stronger-Than-Expected Sales Drive Str... [Published Health News Daily - Jul 15 2014]
Olysio’s Stronger-Than-Expected Sales Drive Str... [Published BioPortfolio - Jul 15 2014]
J&J logs $19.5B in Q2 sales [Published Medical Marketing And Media - Jul 15 2014]
Johnson & Johnson share price dips despite impr... [Published Star Ledger - Jul 15 2014]
Johnson & Johnson's (JNJ) CEO Alex Gorsky on Q2... [Published Seeking Alpha - Jul 15 2014]
J&J Earnings Beat Estimates, But Guidance Mixed [Published Investor's Business Daily - Jul 15 2014]
Blockbuster sales for Hep C drug lift profits f... [Published STLtoday.com - Jul 15 2014]
BREAKING NEWS: J&J books 13% profit rise for se... [Published Pharma Times - Jul 15 2014]
Johnson & Johnson hits 4-week low even as Q2 pr... [Published Proactive Investors USA - Jul 15 2014]
Johnson & Johnson - Strong Results, Driven By P... [Published Seeking Alpha - Jul 15 2014]
J&J’s New Hepatitis C Medicine Pushes Profit Pa... [Published Washington Post - Jul 15 2014]
J&J's powerhouse drug launches drive 21% boost ... [Published FiercePharma - Jul 15 2014]
1 2 3
In Focus
Content Volume
Document Volume


sort by: Date | Relevance
Big Pharma Needs Growth: Two Severely Undervalu... [Published Wall St. Cheat Sheet - Jul 05 2014]
Source: Thinkstock At any given moment, there are literally hundreds of severely undervalued companies that are ripe for takeovers. In this article, I will focus on the pharmaceutical industry, where many investors have borth struck it rich when ...
Inside the Lobbyist War on Drug Prices: What In... [Published Wall St. Cheat Sheet - Jun 10 2014]
Source: Getty Images The pharmaceutical and biotech industries are notoriously tricky for investors. The industry is riskier than many others (such as basic materials or consumer goods), and companies’ successes are largely based on drug approvals, ...
Which of These 10 Best Selling Cancer Drugs Are... [Published Wall St. Cheat Sheet - Jun 06 2014]
Source: Thinkstock If you look at the pharmaceutical industry’s most promising investigational drugs (which you can do right here ), cancer therapies comprise the vast majority of the industry’s recent innovations; a fact which is increasingly important ...
IMAAGEN Data Demonstrate that Abiraterone Aceta... [Published PR Newswire: Health - Jun 02 2014]
HORSHAM, Pa., June 2, 2014 /PRNewswire/ -- Abiraterone acetate (ZYTIGA®) plus prednisone demonstrated statistically significant reductions in PSA levels at six months, the primary endpoint of the IMAAGEN trial, which evaluates the investigational use ...
UK body blocks earlier use of J&J prostate canc... [Published Yahoo! Health News - May 14 2014]
Britain's healthcare cost-effectiveness agency NICE said on Wednesday that a Johnson & Johnson prostate cancer drug, originally invented in Britain, was not worth giving to patients who have yet to receive chemotherapy. Although Zytiga, or ab... ...
1 2 3
Contact Us

Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.